Stockreport

Retrophin to Present Long-Term Data from Phase 2 DUET Study of Sparsentan in FSGS at ASN Kidney Week 2018

RETROPHIN INC  (RTRX) 
Last retrophin inc earnings: 2/24 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.retrophin.com/investor-relations
PDF SAN DIEGO, Oct. 05, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data examining the long-term effects of sparsentan [Read more]